Application note: Size Exclusion Analysis of Tween-containing IgG Formulations (Sigma-Aldrich)
During purification and in final formulation, proteins, including monoclonal antibodies and other biotherapeutic agents, are often in the presence of a low concentration of surfactant (<0.01%) to inhibit protein aggregation or adsorption (1-4). High performance silica-based gel filtration columns, such as 5 micron packed SRT® SEC-300 columns, allow for an accurate assessment of the influence of Tween® 20 or Tween® 80 surfactants on the level of aggregation in protein drug formulations.